



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Lomtegovimab

Cat. No.:	HY-P99710
CAS No.:	2550869-33-3
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 ^{[1][2]} .
In Vitro	Lomtegovimab targets the RBD of SARS-CoV-2 S with a K_D value of 1.09 nM ^[2] . Lomtegovimab shows neutralizing activity with IC_{50} s of 0.001, 0.001, 0.010 μ g/mL for SARS-CoV-2 S D614G, SARS-CoV-2 S B.1.1.7, SARS-CoV-2 BavPat1 (B.1), respectively ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Lomtegovimab (40 mg/kg; i.p. or i.n.; once; three days before infection) protects hACE2-transduced mice from infection with SARS-CoV-2 ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	BALB/c mice (Ad_ACE2-mCherry) ^[2]
Dosage:	40 mg/kg
Administration:	I.p. or I.n.; once; three days before infection
Result:	Led to a complete neutralization of infectious SARS-CoV-2 and slightly reduced amounts of viral RNA in the lungs of treated animals.

REFERENCES

- [1]. Halwe S, et al. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. *Viruses*. 2021 Jul 29;13(8):1498.
- [2]. Halwe S, et al. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. *Viruses*. 2021 Jul 29;13(8):1498.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA